Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab Higher Dose in Primary Progressive Multiple Sclerosis
NCT04548999Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2020
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS), sponsored by Roche. Started Dec 2020; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT04548999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04548999.